PGLA News 0.9299 Progen Pharmaceuticals Limited (PGLA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Progen Pharmaceuticals Limited (PGLA) 0.9299 $PGLA

Age Related Macular Degeneration - Pipeline Review, H2 2013
M2 - Thu Nov 21, 3:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/qks7tx/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2013" report to their offering. 'Age Related Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Age Related Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration. Scope - A snapshot of the global therapeutic scenario for Age Related Macular Degeneration. - A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Age Related Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. Johnson & Johnson F. Hoffmann-La Roche Ltd. Allergan, Inc. Shionogi & Co., Ltd. Lux Biosciences, Inc. RetinaPharma Technologies, Inc. Jeil Pharmaceutical Co., Ltd. Merz GmbH & Co. KGaA BioDiem Ltd ReGenX Biosciences, LLC OXiGENE, Inc. Zenotech Laboratories Limited NeoStem, Inc. Progen Pharmaceuticals Limited and many more... For more information visit http://www.researchandmarkets.com/research/qk...ge_related About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Metastatic Melanoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mttj8/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H2 2012" report to their offering. This data provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Metastatic Melanoma - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of products based on various stages of development ranging from discovery till registration stages - A feature on pipeline projects on the basis of monotherapy and combined therapeutics - Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type - Key discontinued pipeline projects - Latest news and deals relating to the products Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Metastatic Melanoma Overview Therapeutics Development An Overview of Pipeline Products for Metastatic Melanoma Companies Involved in Metastatic Melanoma Therapeutics Development Metastatic Melanoma - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - 3SBio Inc - AVAX Technologies - Abbott Laboratories - Antigenics - BioAlliance Pharma - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics - Eli Lilly and Company - F. Hoffmann-La Roche - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Incyte Corporation - Lorus Therapeutics - Millennium Pharmaceuticals - Molecular Insight Pharmaceuticals - Morphotek - Northwest Biotherapeutics - Novartis AG - Oncolytics Biotech - Ono Pharmaceutical - Osta Biotechnologies - Oxford BioMedica - Pain Therapeutics - Progen Pharmaceuticals Limited - Provectus Pharmaceuticals - Summit Corporation - Vical Incorporated - Viralytics For more information visit http://www.researchandmarkets.com/research/5mttj8/metastatic
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 82

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 58

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 0

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 35

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 108

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading

Top 5 Most Recently Viewed Articles

European Wax Center's Inducement Grants for New Executives

Updated Category News Views 140

Overview of Inducement Grants European Wax Center, Inc. (NASDAQ: EWCZ), known as a leading provider of out-of-home waxing services across the United States, has recently made headlines with its strategic inducement grants. This move comes in light of the recent appointments of key executives, aiming to bolster the company's leadership and operational capabilities....

Continue Reading
Enhancing AI Security: Check Point and Microsoft Partnership

Updated Category News Views 283

Enhancing AI Security Through Strategic Collaboration Check Point Software Technologies Ltd. (NASDAQ: CHKP), a renowned global leader in cyber security solutions, has embarked on an exciting partnership with Microsoft. This collaboration aims to inject enterprise-grade AI security into the Microsoft Copilot Studio, ensuring that organizations can innovate safely and...

Continue Reading
TransMontaigne Partners Strengthen Credit Facility with Extension

Updated Category News Views 238

TransMontaigne Partners LLC Enhances Credit Facility Terms TransMontaigne Partners LLC has recently announced a significant development in its financial strategy. The company has officially closed Amendment No. 4 to its existing Credit Agreement, which illustrates its commitment to optimizing financial operations and enhancing financial stability. Understanding the...

Continue Reading
Red Cross Issues Urgent Call for Blood Donations Beyond Holidays

Updated Category News Views 119

Urgent Appeal for Blood Donations Post-Holiday Season The American Red Cross is currently confronting the threat of a significant blood shortage. As the busy holiday season comes to a close, blood donation rates have plummeted. Unfortunately, the rate at which blood products are being distributed now exceeds the number of donations received, raising concerns about the...

Continue Reading
Weight Loss Drugs Linked to Genetic Hair Loss in Men

Updated Category News Views 34

When weight loss turns hairy, it's not just an old wives' tale. We have some solid evidence from those eggheads at NYU Langone Health, who unearthed this hairy connection between popular weight loss drugs and the glinting domes of the genetically predisposed. Understanding the Hair-Drug Connection The name Ozempic might sound familiar, and not just because it's been...

Continue Reading